2013 Thomas Willis award lecture causation and collaboration for stroke research

Stroke

Volumn 45, Issue 1, 2014, Pages 305-308

  Lo, Eng H ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Brain injuries; Cerebrovascular disorders; Translational research

Indexed keywords

ARTICLE; BASIC RESEARCH; BRAIN; CELL TYPE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); HUMAN; MEDICAL EDUCATION; MEDICAL RESEARCH; NEUROIMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SCIENTIST; STROKE PATIENT;

BRAIN INJURIES; CEREBROVASCULAR DISORDERS; TRANSLATIONAL RESEARCH;

CAUSALITY; COOPERATIVE BEHAVIOR; HUMANS; RESEARCH; STROKE; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84893714667     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/strokeaha.113.001269     Document Type: Article

References (43)

1. Lapchak PA, Zhang JH, Noble-Haeusslein LJ. RIGOR Guidelines: escalating STAIR and STEPS for effective translational research. Transl Stroke Res. 2013;4:279-285.
2. Macleod MR, Fisher M, O'Collins V, Sena ES, Dirnagl U, Bath PM, et al. Good laboratory practice: preventing introduction of bias at the bench. Stroke. 2009;40:e50-e52.
3. O'Collins VE, Donnan GA, Macleod MR, Howells DW. Scope of preclinical testing versus quality control within experiments. Stroke. 2009;40:e497.
4. Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature. 2012;490:187-191.
5. Bath PM, Lees KR, Schellinger PD, Altman H, Bland M, Hogg C, et al; European Stroke Organisation Outcomes Working Group. Statistical analysis of the primary outcome in acute stroke trials. Stroke. 2012;43:1171-1178.
6. Hobin JA, Galbraith RA. Engaging basic scientists in translational research. FASEB J. 2012;26:2227-2230.
7. Zoghbi HY. The basics of translation. Science. 2013;339:250.
8. Fan X, Yu Z, Liu J, Liu N, Hajjar KA, Furie KL, et al. Annexin A2: a tissue plasminogen activator amplifier for thrombolytic stroke therapy. Stroke. 2010;41(10 suppl):S54-S58.
9. Delgado Almandoz JE, Romero JM. Advanced CT imaging in the evaluation of hemorrhagic stroke. Neuroimaging Clin N Am. 2011;21:197-213, ix. 10. Fisher M, Albers GW. Advanced imaging to extend the therapeutic time window of acute ischemic stroke. Ann Neurol. 2013;73:4-9.
10. Heiss WD. The ischemic penumbra: correlates in imaging and implications for treatment of ischemic stroke. Cerebrovasc Dis. 2011;32:307-320.
11. Ning MM, Lopez M, Sarracino D, Cao J, Karchin M, McMullin D, et al. Pharmaco-proteomics opportunities for individualizing neurovascular treatment. Neurol Res. 2013;35:448-456.
12. Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron. 2010;67:181-198.
13. Zhang JH, Badaut J, Tang J, Obenaus A, Hartman R, Pearce WJ. The vascular neural network-A new paradigm in stroke pathophysiology. Nat Rev Neurol. 2012;8:711-716.
14. Barreto G, White RE, Ouyang Y, Xu L, Giffard RG. Astrocytes: targets for neuroprotection in stroke. Cent Nerv Syst Agents Med Chem. 2011;11:164-173.
15. Yemisci M, Gursoy-Ozdemir Y, Vural A, Can A, Topalkara K, Dalkara T. Pericyte contraction induced by oxidative-nitrative stress impairs capillary reflow despite successful opening of an occluded cerebral artery. Nat Med. 2009;15:1031-1037.
16. Guo S, Kim WJ, Lok J, Lee SR, Besancon E, Luo BH, et al. Neuroprotection via matrix-trophic coupling between cerebral endothelial cells and neurons. Proc Natl Acad Sci U S A. 2008;105:7582-7587.
17. Park JA, Choi KS, Kim SY, Kim KW. Coordinated interaction of the vascular and nervous systems: from molecule-to cell-based approaches. Biochem Biophys Res Commun. 2003;311:247-253.
18. Hayakawa K, Pham LD, Katusic ZS, Arai K, Lo EH. Astrocytic highmobility group box 1 promotes endothelial progenitor cell-mediated neurovascular remodeling during stroke recovery. Proc Natl Acad Sci U S A. 2012;109:7505-7510.
19. Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med. 2011;17:796-808.
20. Offner H, Subramanian S, Parker SM, Afentoulis ME, Vandenbark AA, Hurn PD. Experimental stroke induces massive, rapid activation of the peripheral immune system. J Cereb Blood Flow Metab. 2006;26:654-665.
21. Sharp FR, Jickling GC. Whole genome expression of cellular response to stroke. Stroke. 2013;44(6 suppl 1):S23-S25.
22. Guo S, Zhou Y, Xing C, Lok J, Som AT, Ning M, et al. The vasculome of the mouse brain. PLoS One. 2012;7:e52665.
23. Ning M, Sarracino DA, Kho AT, Guo S, Lee SR, Krastins B, et al. Proteomic temporal profile of human brain endothelium after oxidative stress. Stroke. 2011;42:37-43.
24. Lo EH. Degeneration and repair in central nervous system disease. Nat Med. 2010;16:1205-1209.
25. Lo EH. A new penumbra: transitioning from injury into repair after stroke. Nat Med. 2008;14:497-500.
26. Carmichael ST. Cellular and molecular mechanisms of neural repair after stroke: making waves. Ann Neurol. 2006;59:735-742.
27. Zhang ZG, Chopp M. Neurorestorative therapies for stroke: underlying mechanisms and translation to the clinic. Lancet Neurol. 2009;8:491-500.
28. Hess DC, Fagan SC. Repurposing an old drug to improve the use and safety of tissue plasminogen activator for acute ischemic stroke: minocycline. Pharmacotherapy. 2010;30(7 pt 2):55S-61S. 30. Lam TI, Bingham D, Chang TJ, Lee CC, Shi J, Wang D, et al. Beneficial effects of minocycline and botulinum toxin-induced constraint physical therapy following experimental traumatic brain injury. Neurorehabil Neural Repair. 2013;27:889-899.
29. Pekcec A, Yigitkanli K, Jung JE, Pallast S, Xing C, Antipenko A, et al. Following experimental stroke, the recovering brain is vulnerable to lipoxygenase-dependent semaphorin signaling. FASEB J. 2013;27:437-445.
30. Yigitkanli K, Pekcec A, Karatas H, Pallast S, Mandeville E, Joshi N, et al. Inhibition of 12/15-lipoxygenase as therapeutic strategy to treat stroke. Ann Neurol. 2013;73:129-135.
31. Navaratna D, Fan X, Leung W, Lok J, Guo S, Xing C, et al. Cerebrovascular degradation of TRKB by MMP9 in the diabetic brain. J Clin Invest. 2013;123:3373-3377.
32. Dutta P, Courties G, Wei Y, Leuschner F, Gorbatov R, Robbins CS, et al. Myocardial infarction accelerates atherosclerosis. Nature. 2012;487:325-329.
33. Ning M, Lo EH, Ning PC, Xu SY, McMullin D, Demirjian Z, et al. The brain's heart-therapeutic opportunities for patent foramen ovale (PFO) and neurovascular disease. Pharmacol Ther. 2013;139:111-123.
34. L'Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Impagnatiello F, et al. Aging-induced Nrf2-ARE pathway disruption in the subventricular zone drives neurogenic impairment in parkinsonian mice via PI3KWnt/catenin dysregulation. J Neurosci. 2013;33:1462-1485.
35. Miyamoto N, Pham LD, Hayakawa K, Matsuzaki T, Seo JH, Magnain C, et al. Age-related decline in oligodendrogenesis retards white matter repair in mice. Stroke. 2013;44:2573-2578.
36. Zhang Q, Zmasek CM, Godzik A. Domain architecture evolution of pattern-recognition receptors. Immunogenetics. 2010;62:263-272.
37. Packer AM, Roska B, Häusser M. Targeting neurons and photons for optogenetics. Nat Neurosci. 2013;16:805-815.
38. Götz J, Ittner LM. Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci. 2008;9:532-544.
39. Sasaki E, Suemizu H, Shimada A, Hanazawa K, Oiwa R, Kamioka M, et al. Generation of transgenic non-human primates with germline transmission. Nature. 2009;459:523-527.
40. Devor A, Sakadžic S, Srinivasan VJ, Yaseen MA, Nizar K, Saisan PA, et al. Frontiers in optical imaging of cerebral blood flow and metabolism. J Cereb Blood Flow Metab. 2012;32:1259-1276.
41. Deddens LH, Van Tilborg GA, Mulder WJ, De Vries HE, Dijkhuizen RM. Imaging neuroinflammation after stroke: current status of cellular and molecular MRI strategies. Cerebrovasc Dis. 2012;33:392-402.
42. Sugihara G, May R, Ye H, Hsieh CH, Deyle E, Fogarty M, et al. Detecting causality in complex ecosystems. Science. 2012;338:496-500.
43. Hayek FA. The use of knowledge in society. Am Econ Rev. 1945;35:519-530.